Challenges in antimalarial drug discovery
Challenges in antimalarial drug discovery
复制标题
DOI：
10.4155/fmc.11.91
复制
发表时间：
2011-09-01
影响因子：
4.2
通讯作者：
Waterson, David
中科院分区：
文献类型：
--
作者：
Burrows, Jeremy N.;Leroy, Didier;Waterson, David
疟疾是世界上最具破坏性的疾病之一，每年影响近2.25亿人，造成78万多人死亡，其中大多数是5岁以下的儿童。在世界卫生组织支持下，最近呼吁根除疟疾，此后，对抗疟药物发现项目的投资不断增加。这些活动的目的是产生下一代分子，重点是治疗和阻断恶性疟原虫和间日疟原虫的红细胞内外期。本文总结了目前的顶级思维有关起诉这样的努力和疾病的具体考虑，在项目规划。
Malaria is one of the most devastating diseases in the world, affecting almost 225 million people a year, and causing over 780,000 deaths, most of which are children under the age of 5 years. Following the recent call for the eradication of the disease, supported by the WHO, there has been increasing investment into antimalarial drug-discovery projects. These activities are aimed at generating the next generation of molecules focused on the treatment and transmission-blocking of Plasmodium falciparum and Plasmodium vivax endo-and exo-erythrocytic stages of the parasite. This article summarizes the current top-level thinking regarding the prosecution of such endeavors and the disease-specific considerations in project planning.